These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 11295927)

  • 1. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease.
    Chaine B; Neonato MG; Girot R; Aractingi S
    Arch Dermatol; 2001 Apr; 137(4):467-70. PubMed ID: 11295927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
    Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hydroxyurea-induced leg ulcers in patients with chronic myeloproliferative disorders].
    Olesen LH; Pedersen BB
    Ugeskr Laeger; 2001 Dec; 163(49):6908-11. PubMed ID: 11766504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical follow-up of hydroxyurea-treated adults with sickle cell disease.
    Nzouakou R; Bachir D; Lavaud A; Habibi A; Lee K; Lionnet F; Hulin A; Jouault H; Préhu C; Roudot-Thoraval F; Girot R; Galactéros F
    Acta Haematol; 2011; 125(3):145-52. PubMed ID: 21196716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous adverse reactions to hydroxyurea in patients with intermediate thalassemia.
    Zargari O; Kimyai-Asadi A; Jafroodi M
    Pediatr Dermatol; 2004; 21(6):633-5. PubMed ID: 15575845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are we underestimating the leukemogenic risk of hydroxyurea.
    Al-Jam'a AH; Al-Dabbous IA; Al-Khatti AA; Esan FG
    Saudi Med J; 2002 Nov; 23(11):1411-3. PubMed ID: 12506308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea and fetal hemoglobin effect on leg ulcers in patients with sickle cell disease.
    Tolu SS; Crouch A; Choi J; Gao Q; Reyes-Gil M; Ogu UO; Vinces G; Minniti CP
    Ann Hematol; 2022 Mar; 101(3):541-548. PubMed ID: 35039901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of hydroxyurea treatment on cerebral oxygenation in adult patients with sickle cell disease: an open-label pilot study.
    Tavakkoli F; Nahavandi M; Wyche MQ; Castro O
    Clin Ther; 2005 Jul; 27(7):1083-8. PubMed ID: 16154487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin and nail changes in children with sickle cell anemia receiving hydroxyurea therapy.
    O'branski EE; Ware RE; Prose NS; Kinney TR
    J Am Acad Dermatol; 2001 May; 44(5):859-61. PubMed ID: 11312437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea therapy associated with declining serum levels of magnesium in children with sickle cell anemia.
    Altura RA; Wang WC; Wynn L; Altura BM; Altura BT
    J Pediatr; 2002 May; 140(5):565-9. PubMed ID: 12032523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leg ulcer induced by hydroxycarbamide in sickle cell disease: What is the therapeutic impact?
    Soya E; Makowski C; Blaise S
    Int Wound J; 2019 Aug; 16(4):897-902. PubMed ID: 30916480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA damage in blood leukocytes of individuals with sickle cell disease treated with hydroxyurea.
    Friedrisch JR; Prá D; Maluf SW; Bittar CM; Mergener M; Pollo T; Kayser M; da Silva MA; Henriques JA; da Rocha Silla LM
    Mutat Res; 2008 Jan; 649(1-2):213-20. PubMed ID: 17988936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea-induced splenic regrowth in an adult patient with severe hemoglobin SC disease.
    Huang Y; Ananthakrishnan T; Eid JE
    Am J Hematol; 2003 Oct; 74(2):125-6. PubMed ID: 14508799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When should hydroxyurea be used for children with sickle cell disease?
    Mueller BU
    Pediatrics; 2008 Dec; 122(6):1365-6. PubMed ID: 19047256
    [No Abstract]   [Full Text] [Related]  

  • 15. Hydroxyurea for children with sickle cell disease.
    Heeney MM; Ware RE
    Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxyurea in children: present and future.
    Vichinsky EP
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):22-9. PubMed ID: 9317198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sickle cell leg ulcers: a frequently disabling complication and a marker of severity.
    Halabi-Tawil M; Lionnet F; Girot R; Bachmeyer C; Lévy PP; Aractingi S
    Br J Dermatol; 2008 Feb; 158(2):339-44. PubMed ID: 18047512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea.
    Tripathi A; Jerrell JM; Stallworth JR
    Pediatr Blood Cancer; 2011 Jan; 56(1):90-4. PubMed ID: 20922765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.
    Wang WC; Wynn LW; Rogers ZR; Scott JP; Lane PA; Ware RE
    J Pediatr; 2001 Dec; 139(6):790-6. PubMed ID: 11743503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective.
    Sharef SW; Al-Hajri M; Beshlawi I; Al-Shahrabally A; Elshinawy M; Zachariah M; Mevada ST; Bashir W; Rawas A; Taqi A; Al-Lamki Z; Wali Y
    Eur J Haematol; 2013 Jun; 90(6):519-24. PubMed ID: 23489171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.